Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
xGg70QECDMjwMsmM